RxDoctor Payments Data

Jessica Purdom, NP

Nurse Practitioner · Nashville, TNNPI 1932430394

Payments from drug & device makers

$7,044in general payments, 2019–2025

Across 187 payments — averaging $37.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$2K
  • AstraZeneca$730
  • Johnson & Johnson$429
  • Bristol Myers Squibb$313
  • E.r. Squibb & Sons, L.L.C.$288
  • Regeneron Healthcare Solutions, Inc.$257
  • plus $3K from 45 others

What the payments were for

  • Speaking & faculty fees$98014%
  • Travel & lodging$5458%
  • Food & beverage$5,41877%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,044 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$172,779
Medicare patients
75
Services billed
9,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$44,442
XareltoRivaroxaban22$10,930
Hydroxyurea79$2,262
Letrozole95$1,944
Acyclovir54$852
Hydrocortisone16$489
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$459
Dexamethasone20$334
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$302
Levothyroxine Sodium41$295
Anastrozole11$265
Morphine Sulfate ErMorphine Sulfate11$185
Prednisone44$155
Gabapentin20$141
Doxycycline Hyclate12$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$44,44254 claims
Johnson & JohnsonXarelto$429$10,93022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →